April 6, 2017
Eisai obtained exclusive marketing rights in Japan and exclusive marketing and development rights in seven other Asian markets for safinamide (development code: ME2125), a Parkinson’s disease treatment that Meiji Seika Pharma licensed from an Italian firm, the two Japanese companies...read more